Videos

Dr. Erin Murphy talks about a study presented by Dr. Thomas E. Merchant regarding young patients with ependymoma and how they can be treated effectively with a regiment of adjuvant radiation.

Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.

Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.

Minesh Mehta, MBChB, talks about the recently FDA-approved Optune used to treat newly diagnosed glioblastoma. The device utilizes alternating electric fields to inhibit tumor cell growth.

Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.

Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.

Jennifer Eads, MD, assistant professor of Medicine, senior clinical instructor of Medicine, Case Western University, reflects on the phase III RADIANT-4 study, which examined everolimus in advanced nonfunctional neuroendocrine tumors of lung or gastrointestinal origin.

Dr. S. Yousuf Zafar talks about the association between the body mass index of patients who are starting treatment for colorectal cancer and both the progression free survival and overall survival.

Dr. Guy Van Hazel speaks about finding a potential survival advantage for extrahepatic colorectal cancer metastases patients that undergo selective internal radiation therapy.

Dr. Roy S. Herbst discusses a 5 year study focusing on the use of antibodies against EGFR alongside chemotherapy treatments.

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.

Jennifer Montes, MD, NYU Langone Medical Center, discusses a recent study evaluating the relationship between race and breast cancer findings in magnetic resonance imaging (MRI) tests.